The Lancet Rheumatology in conversation with

De: The Lancet Group
  • Resumen

  • Editors at The Lancet Rheumatology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

    A monthly audio companion to the journal, this podcast covers a broad range of topics, from disorders of the immune system to sex and gender in research design, the transitional care for adolescent patients with rheumatic diseases to care for undocumented immigrants, and more.

    © 2025 The Lancet Group
    Más Menos
Episodios
  • Dominique Farge on allogeneic umbilical cord-derived mesenchymal stromal cells for systemic lupus erythematosus
    Apr 25 2025

    This is the second episode of a mini series on cell-based therapies in rheumatology, with Prof. Dominique Farge discussing the use of allogeneic umbilical cord-derived mesenchymal stromal cells (MSCs) as treatment for systemic lupus erythematosus (SLE).

    We cover the limited options currently available for people with severe or refractory SLE, the complexities in using MSCs, Prof. Farge's recent study results, and how these results fit in with the evidence available, as well as the future for this area of research.

    You can find the study here:

    https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00298-4/fulltext?dgcid=buzzsprout_icw_podcast_25-04-25_lanrhe

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
    26 m
  • Rebecca Marsh and Grant Schulert on allogeneic HSCT for children with refractory sJIA and associated lung disease
    Mar 24 2025

    The first episode of a mini series on cell-based therapies in rheumatology, with Prof Rebecca Marsh and Grant Schulert discussing the use of allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease.

    Read the full article:

    https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00275-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
    19 m
  • Bryant England on advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease
    Feb 24 2025

    Dr Bryant England discusses the use of TNF-inhibitor versus non-TNF inhibitor biological or targeted synthetic DMARDs for treatment of rheumatoid arthritis-associated ILD, and the effects on survival and respiratory hospitalisation outcomes.

    Read the full article:

    https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00265-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanrhe

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Más Menos
    9 m
adbl_web_global_use_to_activate_webcro805_stickypopup

Lo que los oyentes dicen sobre The Lancet Rheumatology in conversation with

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.